Clin Chim Acta by Wei, Binnian et al.
A high-throughput robotic sample preparation system and 
HPLC-MS/MS for measuring urinary anatabine, anabasine, 
nicotine and major nicotine metabolites☆
Binnian Wei*, June Feng*, Imran J. Rehmani, Sharyn Miller, James E. McGuffey, Benjamin 
C. Blount, and Lanqing Wang
Tobacco and Volatiles Branch, Division of Laboratory Sciences, National Center for 
Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States
Abstract
Background—Most sample preparation methods characteristically involve intensive and 
repetitive labor, which is inefficient when preparing large numbers of samples from population-
scale studies.
Methods—This study presents a robotic system designed to meet the sampling requirements for 
large population-scale studies. Using this robotic system, we developed and validated a method to 
simultaneously measure urinary anatabine, anabasine, nicotine and seven major nicotine 
metabolites: 4-Hydroxy-4-(3-pyridyl)butanoic acid, cotinine-N-oxide, nicotine-N-oxide, trans-3′-
hydroxycotinine, norcotinine, cotinine and nornicotine. We analyzed robotically prepared samples 
using high-performance liquid chromatography (HPLC) coupled with triple quadrupole mass 
spectrometry in positive electrospray ionization mode using scheduled multiple reaction 
monitoring (sMRM) with a total runtime of 8.5 min.
Results—The optimized procedure was able to deliver linear analyte responses over a broad 
range of concentrations. Responses of urine-based calibrators delivered coefficients of 
determination (R2) of >0.995. Sample preparation recovery was generally higher than 80%. The 
robotic system was able to prepare four 96-well plate (384 urine samples) per day, and the overall 
method afforded an accuracy range of 92–115%, and an imprecision of <15.0% on average.
Conclusions—The validation results demonstrate that the method is accurate, precise, sensitive, 
robust, and most significantly labor-saving for sample preparation, making it efficient and 
practical for routine measurements in large population-scale studies such as the National Health 
and Nutrition Examination Survey (NHANES) and the Population Assessment of Tobacco and 
Health (PATH) study.
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1. Introduction
Humans are exposed to complex chemicals from both natural and anthropogenic sources 
that exist in both ambient surroundings and indoor microenvironments through daily 
inhalation, ingestion and dermal absorption. Tobacco smoke, for example, contains more 
than 8000 chemicals [1], many of which are associated with adverse health outcomes, such 
as cancer, respiratory and cardiovascular diseases, in both smokers and nonsmokers [2–5].
Assessing the exposure to and risk from chemicals caused by tobacco use by external 
measurements, e.g. their indoor air concentrations and surface loadings, is always 
challenging. Biomonitoring, measuring trace levels of suspected chemicals in biological 
matrices (i.e., blood, urine, and tissues), is able to provide the actual absorbed levels of these 
chemicals in human fluids and tissues, providing the “gold standard” for assessing exposure 
to chemicals [6].
However, biological samples are usually complicated matrices, containing thousands of 
chemicals from external exposure, their metabolites, and a number of other endogenous 
constituents, such as proteins, phospholipids and salts, which could potentially interfere with 
the analysis. As a result, biological samples require specific pre-treatment procedures to 
minimize or eliminate potential interferences and matrix effects and thus to improve the 
sensitivity and specificity for measuring the target analytes [7,8]. Typical pre-treatment 
techniques include liquid–liquid extraction (LLE) [9,10], solid phase extraction (SPE) [11–
13], soxhlet extraction [14], supercritical fluid extraction (SFE) [15], microwave-assisted 
extraction (MAE) and pressurized solvent extraction (PSE) [16]. The robotic sample 
preparation procedure described here uses a validated acetone precipitation step to deplete 
endogenous proteins, salts and phospholipids and to remove the exogenous enzyme that is 
added to the urine samples to hydrolyze conjugates [17].
Target analytes in pretreated samples are often chromatographically resolved using gas 
chromatography (GC) or high-performance liquid chromatography (HPLC), which is often 
coupled with detectors varying from the ultraviolet (UV)/visible spectroscopy and single 
quadrupole mass spectrometry (MS) [10,18] to tandem MS/MS [11,19–21]. MS/MS 
provides a more sensitive and selective means for simultaneously measuring multiple 
analytes.
Most sample preparation methods characteristically involve intensive and repetitive labor, 
which is inefficient when preparing large numbers of samples from population-scale studies. 
These types of studies include the National Health and Nutrition Examination Survey 
(NHANES) designed to assess the health and nutritional status of adults and children in the 
United States [22], and the Population Assessment of Tobacco and Health (PATH) study 
aimed to assess the behavioral, social, and health impact of tobacco use [23]. The need for 
high through-put sample analysis motivated the development of a robotic procedure for 
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pretreatment of biological urine samples, specifically for measurement of anatabine 
(ANAT), anabasine (ANAB), nicotine (NIC) and seven major nicotine metabolites in the 
present study.
Nicotine, a primary tobacco-specific alkaloid in tobacco and tobacco smoke, does not 
directly cause most diseases associated with tobacco use. However, due to its addictiveness, 
users often choose to continuously/repeatedly use tobacco products, exposing themselves to 
the carcinogens and bioactive compounds in tobacco [24]. Thus, measuring nicotine and its 
major metabolites can determine tobacco exposure, and will play an important role in 
assessing tobacco exposure and making control regulations. Nicotine is absorbed by 
smokers mainly through direct inhalation of the mainstream smoke [24]. Non-smokers also 
can be involuntarily exposed to second-hand smoke (SHS), or even third-hand smoke 
through inhalation, dermal absorption, and dust ingestion [25, 26]. Nicotine in mammals is 
metabolized predominantly into cotinine (COT) (Fig. S1), accounting for approximately 70–
80% of NIC dose. COT is further converted through various metabolism pathways, (e.g., 
cytochrome P450), to form other metabolites, including trans-3′-hydroxycotinine (3HC, 
accounting for 40–49% of NIC dose), cotinine-N-oxide (CNO, 2–5%) and norcotinine 
(NorCOT, 1–2%), leaving approximately 22–32% total COT in urine. Another three major 
NIC metabolites include 1-(3-Pyridyl)-1-butanol-4-carboxylic acid (HPBA, 7–9%), 
nicotine-N-oxide (NNO, 4–7%), and nornicotine (NorNIC, 0.4–0.8%) [24].
Tobacco plants synthesize nicotine as well as minor tobacco alkaloids such as ANAT and 
ANAB. This pattern of alkaloids is characteristic of tobacco leaf and tobacco products. 
Tobacco use leads to concurrent exposure to NIC, ANAT, and ANAB, as well as the 
presence of measurable levels of biomarkers of exposure to these alkaloids [27]. Not 
surprisingly, ANAT and ANAB are variably glucuronidated [17] and excreted in the urine 
with elimination half-lives similar to those for nicotine and its metabolites. Thus the 
presence of biomarkers of exposure to NIC, ANAT, and ANAB has been validated as 
proving tobacco product use [27]. Conversely, nicotine replacement therapy uses 
pharmaceutical-grade nicotine that is essentially free of minor tobacco alkaloids; therefore 
subjects abstaining from tobacco use and undergoing nicotine replacement therapy have 
urinary ANAT and ANAB levels <2 ng/ml.[27] Based on these findings ANAT and ANAB 
are validated biomarkers for identifying non-compliance for participants using NIC 
replacement therapy (NRT) [17,27]. Our specific aim in this study was to develop and 
validate a robotic sample preparation method and a HPLC-MS/MS analytical method to 
simultaneously determine the urinary concentrations of NIC and seven major NIC 
metabolites in samples from NHANES and PATH studies including both “free” (non-
conjugated) and “conjugated” (mostly glucuronide) forms. Our automated method was able 
to prepare four 96-well plates (384 samples) per day simultaneously with a sample 
preparation recovery higher than 80%. The method was optimized to provide a wide linear 
dynamic range for analyte concentrations. Urine calibrators produced coefficients of 
determination (R2) of greater than 0.995. The accuracy, precision, and robustness make this 
method efficient and practical for large population-scale studies.
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2. Materials and methods
2.1. Reagents and standards
Acetone, ammonium hydroxide, ammonium acetate and ß-glucuronidase (type H-1, Helix 
pomatia and Escherichia coli, type IX-A) were from Sigma-Aldrich. Acetonitrile and 
methanol were from Honeywell; hydrochloric acid was purchased from Fisher Scientific and 
HPLC water was from J.T. Baker. Ten native analytes, including NIC, HPBA, CNO, NNO, 
3HC, NorCOT, COT, NorNIC, ANAT and ANAB and their corresponding isotopically 
labeled standards were from Toronto Research Chemicals. Details for product sources are 
listed in Tables S1 and S2.
2.2. Biological samples
Urine samples from smokers (n = 40) used to develop study methods were collected with no 
identifiable information by Tennessee Blood Services. Two hundred urine samples from 
non-smokers were collected from anonymous donors with Institutional Review Board (IRB) 
approval. Since the smoker urine samples were purchased from commercial sources, the 
analysis of these samples did not meet the definition of human subjects as specified in 45 
CFR 46.102 (f) [28].
2.3. Blank urine pool preparation and Quality control (QC) materials
Blank urine used as matrix material for calibration standards and quality control (QC) was 
prepared using the following procedures: First, urine samples collected from non-users (n = 
200) were screened to eliminate those samples with detectable levels of the analytes. Then 
the samples containing non-detectable levels of the target analytes were pooled to form a 
blank urine pool and held at 4 °C overnight to ensure thorough mixing.
High and low QC pools made from the collected smoker urine samples (n = 40) were 
prepared according to the following procedures: First, we screened smoker urine samples to 
determine the analyte concentrations in each sample; then, we combined different samples 
and diluted them using pooled blank urine to obtain a desired concentration for each analyte. 
It was necessary to spike some pools with native stock solutions to obtain the desired 
concentrations of some analytes in the pools when their concentrations did not yield high 
enough concentration levels. Aliquoted QC pools were analyzed daily for two months to 
obtain analyte means and standard deviations.
2.4. Standard preparation
Individual stock solutions were gravimetrically prepared for both native and labeled 
standards using certified materials in acidified HPLC water (0.1% hydrochloric acid in 
HPLC water). We prepared 12 calibration standard solutions by diluting the native stock 
solutions with pooled blank urine. We prepared internal standard spiking solution by mixing 
isotope-labeled stock solutions and diluting them with HPLC water. Details about the 
calibration ranges and isotope-labeled spiking internal standards are provided in Table 1.
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2.5. HPLC mobile phase
Fresh mobile buffer “A” was prepared based on the volume needed for the total batch 
samples. For a total volume of 1.0 l buffer, we added 10 ml of 650 mmol/l of stock 
ammonium acetate solution to 990 ml of HPLC-grade water, yielding a running buffer of 6.5 
mmol/l ammonium acetate. We adjusted the pH of the solution to 10.0 with ammonium 
hydroxide solution. Mobile phase “B” was 100% acetonitrile. Buffer solutions were 
degassed for 5 min using an ultrasonic water bath.
2.6. β-Glucuronidase solution
Fresh enzyme solution (16.7 units/μl) was prepared by weighing 28.5 mg of β-glucuronidase 
(type H-1, H. pomatia) in 6.5 ml of 0.5 mol/l ammonium acetate (pH 5.1 adjusted with 
glacial acetic acid, stored at 4 °C), which resulted in 1000 units in 60 μl solution. It was 
noted that enzyme solution should be mixed gently by inversion and prepared at least 30 min 
before use to ensure that all enzyme powder has dissolved.
2.7. Instrumentation
2.7.1. Robotic sample preparation system—The robotic sample preparation system 
was built in an enclosure (1.5 m deep, 2.3 m wide and 2.2 m high), containing a Mitsubishi 
robot, a Sciclone G3 automated liquid-handling workstation (PerkElmer), a Rotanda 460 
auto-centrifuge, a thermal sealer (Thermo Scientific, USA), four Inheco incubators (Inheco), 
a TurboVap 96 concentration evaporator workstation (Biotage), a capper/de-capper 
(FluidX), and a 2D barcode reader (FluidX). Fig. 1 shows the scheme of the robotic sample 
preparation system. Additional information is provided in supporting materials, and more 
details can be obtained upon request.
2.7.2. Analytic instruments—We achieved chromatographic separation using a Gemini-
NX column (100 mm × 3.0 mm, particle size 3 μm, Phenomenex) on a HPLC system 
consisting of a DGU-20A5R degasser, two LC-20ADXR pumps, a SIL-30AC autosampler, 
and a CTO-20AC column oven (Shimadzu Corp.). The gradient system included 6.5 mmol/l 
of ammonium acetate (pH 10.0) (buffer A), and acetonitrile (organic phase) at a flow rate of 
0.65 ml/min. We kept the column temperature at 40 °C during the entire analysis. Total 
chromatographic run time was 8.5 min; a sample chromatogram is shown in Fig. 2. Details 
about the HPLC gradient conditions are provided in Table 3S.
We performed tandem MS analysis on an ABSciex triple quadrupole 5500 mass 
spectrometer with a TurboIonSpray source (ABSciex). We operated the MS in electrospray 
(ESI) positive mode using scheduled MRM data acquisition. We monitored two MRM 
transitions for each analyte and one for the isotope labeled internal standard. The source/gas 
specific parameters applied in the method are listed in Table S4, and the analyte specific 
parameters and MRM transitions are provided in Table S5.
Analyst software (version 1.6.2) was employed for data acquisition, and data quantitation 
was performed using Indigo Ascent Automated Data Analysis and Review software — a 
web based integration software (Indigo Biosystems). Calibration curves were constructed 
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using peak area ratios of analytes to corresponding internal standards for each batch via 
linear least-squares regression with a 1/x weighting factor.
2.8. Robotic sample preparation and cleanup principle
All sample preparation materials, including samples, plates and tips, etc., were automatically 
handled by the Mitsubishi robot, and samples were tracked throughout the process using the 
2D barcode printed on each sample vial (Fig. 1). First, 50 μl of internal standard solution 
(ISTD concentrations were listed in Table 1 and their sources were listed in Table S2) was 
transferred to each cell in a 96-deepwell plate. Then, 100 μl of each sample (e.g., urine, QCs, 
calibration standards and laboratory control blanks) and 60 μl enzyme solution were 
transferred to each cell in the 96-deepwell plate, and mixed well, followed by enzymatic 
hydrolysis at 45 °C for 12 h. After the plate was cooled to room temperature, 450 μl cold 
acetone (−20 °C) was added to each well. The plate was held at −20 °C for 30 min followed 
by centrifugation at −20 °C for 30 min, and then 180 μl of the supernatant in each well was 
transferred into a second 96-well plate and evaporated for about 12 min to remove acetone. 
Finally, 250 μl HPLC water was added into each well prior to HPLC injection. Details of the 
sample preparation on the automation system are provided in the supporting materials.
2.9. Quality control program
Following quality control (QC) measures were used to ensure the reliability of the data: 1). 
calibration standards (STD) and QC samples were kept at or below −60 °C for long-term 
storage; 2). STDs, QCs and laboratory control blanks were prepared and analyzed in the 
same manner as the urine samples in each analytical batch; 3). Samples were calibrated 
using 12-point curves, and both calibration standards and QC samples were prepared in 
pooled urine samples to correct for potential matrix effects; 4). Calibration curves were 
regularly assessed using standard solutions prepared by spiking chemicals from a second 
commercial source or lot in nonsmoker urine pools; 5). Instruments were regularly evaluated 
to maintain high sensitivity. Specifically, the mass spectrometer source was cleaned weekly, 
usually on Monday of each week, and the MS tuning was routinely conducted semi-
annually. But any maintenance was also done on an as-needed basis or before an unusual 
low response for any of the analyte was seen; 6). The data were quantified using Indigo 
customized for this method for automatic peak selection and integration. Specifically, 
following rules were customized for this method to ensure the data quality, including ion 
ratio (qualitative peak area/quantitative peak are), thresholds such as blank contamination, 
extreme concentration, calibration linearity, standard concentration deviation, instrumental 
sensitivity, QC concentration range, retention time, carry over, and maximum instrument 
intensity; and 7). The QC program of the Division of Laboratory Sciences, National Center 
for Environmental Health (NCEH) at CDC, were used to evaluate the accuracy and 
precision of the analyte concentrations in QC samples [29].
3. Results and discussion
The robotic sample preparation system we present in the study provides a technically 
feasible means to avoid extensive and repetitive manual work during routine biological 
sample preparation required for large numbers of samples from population-scale studies 
Wei et al. Page 6
Clin Chim Acta. Author manuscript; available in PMC 2015 July 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(e.g. NHANES and PATH). We applied this system further to determine ANAT, ANAB, 
NIC and its seven major metabolites in human urine using a modified method based on the 
study by McGuffey et al. [17]. We conducted the modifications aimed to increase the 
throughput using the robotic sample preparation system, mainly in 2 aspects: Liquid 
chromatography (column, buffer and gradient) and enzymatic hydrolysis. To ensure the 
reliability of the automated system when applied to the method, we then evaluated the 
sensitivity, linearity, accuracy, precision, sample preparation recovery, sample stability 
(light, temporal and thermal) and carry-over.
3.1. Mobile phase and liquid chromatography
Several major factors influencing chromatography, e.g. buffer pH and gradient, were tested 
to ensure that we achieved the best resolution and reduced the analysis time. Those factors 
are not independent but mutually related. In this study, we selected a Gemini-NX column 
with moderate dimension (100 × 3.0 mm, 3.0 μm) and adjusted the gradient to obtain a 
running time of 8.5 min per sample (Table 2). Meanwhile, we reduced HPLC injection 
volume to 2 μL to avoid overload and detector saturation. The flow rate was set to 0.65 ml/
min. Responses of all analytes on the detector and their resolutions were compared at 
different buffer pH values from 3.5 to 10.5 as presented in Fig. 3.
Most previous studies used acidic buffers in their methods for measuring urinary NIC and its 
metabolites [12,21]. As reported in those studies and indicated in Fig. 3, many analytes 
overlap under acidic conditions. Although quantitating the analytic concentrations using 
different MRM transitions was possible, the following factors could cause large 
uncertainties and variations in calculated concentrations: first, NIC and many of its 
metabolites always share the same MRM transitions that give the highest peak responses. To 
differentiate analytes, different MRM transitions should be selected for each analyte. 
Inevitably, some MRM transitions with lower peak response must be selected for certain 
analytes, which will lead to lower sensitivities for those analytes. Second, biological samples 
are always complicated matrices. Potential interferences that have the same MRM 
transitions and retention times can distort the peak shapes and deteriorate the chromatograph 
baseline, resulting in larger uncertainties and variations in peak picking and integrating. 
Finally, low resolutions from analyte to analyte and from analytes to interferences may also 
increase the ion suppression, and further reduce the sensitivity.
However as shown in Fig. 3, basic buffer (pH > 9.6) can significantly improve the 
chromatographic resolutions. A buffer with higher pH greater than 10.0 (e.g. 10.5) can 
reduce the peak tailing to some extent, especially for NIC, NorNIC, ANAB and ANAT as 
the column ages (typically >1200 runs). Using this method, the retention time for the first 
eluted analyte, HPBT, slowly shifted to the void volume after 800–1200 runs, the usual 
retention time in which polar matrix materials are eluted. Consequently, ion suppression 
gradually increased for HPBA, which required replacing the old column before heavy tailing 
issues occurred. To consider the theoretical pH range for ammonia–ammonium acetate 
buffer (8.2–10.2) and the instrument pH tolerance, to maximize the column life and the 
method ruggedness, and to delay the elution time of HPBA from polar waste, we chose a 
buffer pH of 10.0 in this method.
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3.2. Enzymatic hydrolysis
Hydrolysis is a critical step to “free” the analyte from all conjugated forms, such as 
glucuronide (Fig. S1) to obtain the “total” concentration for each analyte. We tested two 
types of enzymes, E. coli and H. pomatia, and evaluated their hydrolysis performances by 
changing the enzyme amount added to each sample at three incubation temperatures: 37°, 
45° and 50 °C (Figs. 4 and S2). For those 10 analytes with same amount added to each 
sample at 37° and 45 °C, E. Coli generally has higher activity than H. Pomatia. However, 
with a temperature increase from 45° to 50 °C, the activity of E. Coli slowly decreases while 
the activity for H. Pomatia slowly increases. Thus, the usable working incubation 
temperature range for H. Pomatia is wider than that for E. Coli. Usually with the same 
conditions for other parameters, hydrolysis takes longer to complete at 37 °C than at 45 °C 
for both enzymes. To allow completion of the enzymatic hydrolysis within 12 h, we selected 
45 °C as the incubation temperature.
Acid hydrolysis (hydrochloric acid) performance was also tested to investigate whether acid 
hydrolysis can typically reduce the incubation duration. However, we found that the 
hydrochloric acid did not complete the hydrolysis for urinary 3HC-O-β-D-glucuronide within 
even a longer time, indicating that the efficacy of acid hydrolysis could be associated with 
the specific analyte. In addition, a liquid–liquid extraction or SPE cleanup is generally 
necessary after acid hydrolysis to remove the acid which is not compatible with the 
instrument. Those sample cleanup procedures are not as amenable to automation as the 
validated acetone precipitation procedure used with enzyme hydrolysis.
3.3. Sensitivity and linearity
Our preliminary studies showed that urinary concentration varied vastly from one analyte to 
another. 3HC, COT and NIC had the highest urinary concentrations that can exceed 12,000 
ng/ml. Urinary concentrations for HPBA, CNO and NNO could be as high as 5000 ng/ml; 
the concentrations for NorCOT and Nornic were typically lower than 1000 ng/ml. Urinary 
concentrations for ANAT and ANAB were on average lower than 100 ng/ml. Usually high 
concentrations can saturate the MS detector, while low concentrations may fall below the 
limit of detection (LOD). To determine all 10 analytes simultaneously, and to increase their 
dynamic linear ranges to reduce sample re-run rate, we detuned analytes with high 
concentrations (Table 3) and reconstituted processed samples with 250 μl water prior to 
HPLC injection. We did not detune ANAT and ANAB to maintain their sensitivities 
because they have relatively low urinary concentrations. Typical linear equations with 
correlation coefficients (R2) that exceeded 0.995 are also presented in Table 1.
3.4. LODs and LOQs
The LOD and the limit of quantitation (LOQ) for all analytes were determined by preparing 
and analyzing four low spiked urine pools. The standard deviation (SD) of each pool (Y 
axis) was plotted against the concentration (X axis). The estimate of the SD at zero analytic 
concentration (S0) was defined as the Y-intercepts. LODs and LOQs were calculated as 
three times and 10 times S0 [30–32], respectively, as given in Table 1. Notably, the 
sensitivities for those detuned chemicals were inevitably lower compared with those 
sensitivities under optimized conditions. Since this method was developed to evaluate urine 
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samples from smokers and persons heavily exposed to SHS, those LOQs were sufficient to 
obtain high detection rates.
3.5. Accuracy and imprecision
Intra- and inter-day accuracy (expressed as a percent of the target concentration) and 
imprecision for each analyte were evaluated with 5 different concentrations distributed 
across the entire calibration curves of measured analytes prepared by spiking known 
amounts of analytes in the pooled blank urine (Table S7). Specifically, inter-day accuracy 
and imprecision were evaluated with 16 replicates for each concentration level within an 
analytical batch each day. The inter-day data was assessed with three separate analytical 
batches over 3 consecutive days. The total accuracy and imprecision were calculated with all 
data sets (n = 48) (Table 3). The overall intraday imprecision was < 10%, except for a few 
samples at low concentrations, for which the imprecision was around 15%.
3.6. Sample preparation recovery and carry-over
Two sets of samples, including three replicates from each of the low, medium and high 
concentration pools, were prepared to determine the recovery for each analyte on the 
automated sample preparation and the potential carry-over on the HPLC-MS/MS system 
using a method similar to that used by McGuffey et al. [17]. Briefly, deuterated internal 
standard solution was added to one set of samples at the beginning of the sample 
preparation; the solution was added to the other set immediately before injection. Sample 
preparation recovery (%) was calculated by comparing the average peak area of processed 
internal standards with the average peak area of unprocessed internal standards.
Chemicals can be lost through procedures such as absorption, precipitation and evaporation 
during the entire sample preparation. Take the evaporation procedure for example, because 
of the variety of the volatility for those analytes included in the method, the loss fraction for 
each analyte during evaporation is different. Smoker urine samples usually have high 
analyte concentrations, which, in most cases, still allow enough mass amounts in prepared 
samples to be detected by MS even when the sample preparation recovery is low. However, 
lower recovery will simultaneously lead to lower detection rate, especially for those 
chemicals with lower urinary concentrations, such as anatabine and anabasine. Thus, these 
chemicals may not be detected even in light smokers. In this study, we strictly set the 
evaporation parameters to just remove the acetone that was added for precipitation so as to 
avoid drying the residuals. This process ensures acceptable detection rates for all analytes 
and good consistence for sample preparation. Average recovery measured for all analytes 
was greater than 87%. NNO and NorCOT had the 2 highest recoveries greater than 92%, 
and NIC had the lowest recovery of 80%. These results from the automation system are 
comparable to those reported in previous studies using the manual methods [12,21].
To investigate the carry-over, we used the same sample pools that were used for determining 
the sample preparation recovery. After the injection of each sample (low, median, high), 
three blank urine samples were injected. The carry-over was determined by comparing the 
average peak area of each native analyte in the first blank urine sample with the average 
peak area for the native analyte in those processed samples (low, median, high). Validation 
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results indicated that carry-over for each analyte was negligible at all levels (high, median 
and low).
3.7. Thermal, temporal, light and freeze–thaw stability
All samples were stored at or below −60 °C. Because the samples were prepared at room 
temperature and could be potentially exposed to light during processing, we evaluated 
thermal, temporal and light stability for each analyte (Figs. S3 and S4, supporting materials). 
These results indicated that all measured analytes were stable during the entire sample 
preparation procedures under laboratory conditions, including the 12-h incubation at 45 °C, 
and were stable for at least 2 months at ≤− 20 °C. Processed samples were stable for at least 
1 week in the liquid chromatography autosampler at 4 °C.
Urine samples might undergo multiple freeze–thaw cycles when it becomes necessary to re-
prepare or aliquot them. We tested two urine pools to measure whether this procedure could 
affect target analyte concentrations. The results indicated that no significant effects of 
freeze–thaw cycles (up to 25 cycles) were detected on the targeted analyte concentrations 
(Table S6). However, we suggest that all samples be appropriately capped to avoid any loss 
or condensation due to liquid evaporation during the freeze–thaw procedure.
3.7.1. QC-charts—Using the robotic system, we characterized and analyzed two QC pools 
(high and low) on 20 individual analytical batches using the optimized HPLC-MS/MS 
method for 12 consecutive weeks. QC charts for all analytes are shown in Figs. S5A and 
S5B, demonstrating excellent accuracy, precision and ruggedness of this method.
3.8. Application to smoker urine samples
We applied the fully validated method to measure the total concentrations (“free” plus 
“conjugated” forms) for those 10 analytes in a set of urine samples from smokers (n = 40). 
Table 2 shows the concentration distributions for each target analyte. The highest values for 
both geometric mean (GM) and median were observed for 3HC (GM: 6236 ng/ml; median: 
6695 ng/ml), followed by COT (GM: 3223 ng/ml; median: 3555 ng/ml). NIC had the third 
highest GM of 1178 ng/ml and median of 1485 ng/ml. Both GMs and medians for HPBA, 
CNO and NNO were lower than 1000 ng/ml and those for NorCOT and NorNIC were < 150 
ng/ml.
Estimated molar percentages of the summation of the molar concentrations for NIC and its 
metabolites are shown in Fig. 5. On average, 3HC accounted for 48% of the molar fraction 
in the total molar concentrations in this set of samples, followed by COT and NIC, 
accounting for 27% and 11%, respectively. Molar fractions for HPBA, CNO, NNO, NorNIC 
and NorCOT were 5%, 4%, 3%, 1% and 1%, respectively. These percentages were 
comparable to those observed results in metabolism studies in mammals [24].
Nicotine and its metabolites can be detected in urine samples from not only cigarette 
smokers but also from persons using nicotine replacement therapy with smoking cessation 
drugs (e.g. nicotine patch, gum, nicotine inhaler, and nasal spray). However, ANAT and 
ANAB predominantly exist in cigarette products and less frequently in smokeless products. 
A previous study suggested a cut-point of 2 ng/ml to differentiate cigarette smokers and 
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persons undergoing nicotine replacement therapy [27]. Using this cut-point, only two 
persons among those 40 samples had concentrations for both ANAB and ANAT <1.1 ng/ml, 
indicating that they might have been undergoing nicotine replacement therapy when the 
urine samples were collected. Five persons had concentrations around 2 ng/ml for ANAT 
and ANAB, which could have been caused by either light cigarette smoking or exposure to 
heavy SHS when the urine samples were collected.
4. Conclusions
In this study, we presented a fully automated sample preparation system that was able to 
circumvent the intensive and repetitive labor normally required for large numbers of 
samples from population-scale studies (e.g. NHANES and PATH). The automated system 
was able to simultaneously prepare four 96-well plate (384 urine samples) per day with a 
mean preparation recovery greater than 80%. A HPLC-ESI-MS/MS method was then used 
to measure anatabine, anabasine, nicotine and seven major nicotine metabolites in human 
urine. Wide calibration linear dynamic ranges can reduce the sample re-preparation rate 
significantly. Validation results demonstrate that this method is robust, accurate, precise, and 
efficient for preparing and analyzing routine urine samples.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
The scheme for the robotic sample preparation system (back side-1A, front side-1B).
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Fig. 2. 
A representative chromatograph for a urine sample (HPBA: 3.50; CNO: 6.0; NNO: 8.0; 
3HC: 25; NorCOT: 3.0; COT: 15; NorNIC: 3.0; ANAT: 1.0; ANAB: 0.80; and NIC: 20. 
Unit: ng/ml).
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Fig. 3. 
Effects of buffer (A) pH on the retention time for each analyte assessed using the running 
gradient in Table S3.
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Fig. 4. 
Enzymatic hydrolysis performances between E. Coli (A) and H. Pomatia (B) for Urinary 
3HC-O-β-D-glucuronide (critical glucuronide determining the enzyme amount and 
incubation duration) at 37, 45 and 50 °C.
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Fig. 5. 
Estimated median molar percentages for nicotine metabolites over the total molar 
concentrations.
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Table 1
Native calibration range, Isotope-labeled internal standard concentration (ISTD), typical calibration equation, 
limit of detection (LOD) and limit of quantitation (LOQ) (unit: ng/ml).
Analyte ISTD conc. ng/ml Calibration range ng/ml Calibration equationa R 2 LOD LOQ
HPBA 1326 1.0–6000 yresponse_ratio = 6.9556e (—4) · xconc + 3.5874e (—4) 0.99926 0.40 1.40
CNO 456 1.5–4500 yresponse_ratio = 6.1846e (—4) · xconc − 84057 e (—5) 0.99924 0.60 2.00
NNO 304 2.0–6000 yresponse_ratio = 4.0443e (—4) · xconc + 2.0414e (—4) 0.99973 0.75 2.50
3HC 1290 3.0–55,000 yresponse_ratio = 7.5744e (—5) · xconc + 8.9021e (—7) 0.99986 2.85 9.50
NorCOT 726 0.75–1600 yresponse_ratio = 2.1099e (—3) · xconc + 7.6984e (—4) 0.99997 0.33 1.10
COT 344 1.5–25,000 yresponse_ratio = 9.7285e (—5) · xconc + 7.0885e (—5) 0.99995 1.40 4.60
NorNIC 571 0.0–1200 yresponse_ratio = 2.5500e (—3) · xconc + 2.8787e (—2) 0.99994 0.75 2.50
ANAT 367 0.25–800 yresponse_ratio = 4.1524e (—3) · xconc + 5.3714e (—4) 0.99975 0.12 0.40
ANAB 507 0.20–800 yresponse_ratio = 3.6507e (—3) · xconc + 4.1881e (—3) 0.99983 0.15 0.50
NIC 5474 0.0–20,000 yresponse_ratio = 1.3560e (—4) · xconc + 7.6751e (—4) 0.99999 3.15 10.5
a
Response-ratio: native response divided by ISTD response; xconc: sample concentration, ng/ml.
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Table 2
Concentration distributions (ng/ml) for anatabine, anabasine, nicotine and major nicotine metabolites in 40 
smoker urine samples.
Analyte GM Min 5th 25th 50th 75th 95th Max
HPBA 636 44.2 110 397 685 1140 2205 3070
CNO 501 53.9 121 297 573 807 1540 2790
NNO 408 26.2 65.4 208 469 724 2474 3230
3HC 6236 1010 1642 3893 6695 11125 18,785 30,800
NorCOT 111 15.8 27.3 75.0 117 175 368 482
COT 3224 267 1106 2175 3555 5383 8080 21,200
NorNIC 74.2 5.31 11.5 50.0 80.3 148 365 468
ANAB 16.2 0.80 1.97 10.2 17.7 39.5 69.8 73.8
ANAT 8.61 0.26 1.73 5.47 10.1 18.9 33.8 38.3
NIC 1178 28.1 108 623 1485 3395 6071 7110
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